Evidence map›Paper›PMID 41476587›Full record

ArticleFrontiers in oncology2025

Breast cancer occult in renal cell carcinoma: a case report of a rare tumor-to-tumor metastasis and literature review.

Bin Huang, Yin Han, Yanjie Zhang, Hongsheng Liu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bin HuangDepartment of Pathology, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang, China.
Yin HanDepartment of Pathology, Shanghai First Maternal and Infant Health Care Hospital, Shanghai, China.
Yanjie ZhangDepartment of Pathology, The Second People's Hospital of Xiaoshan District, Hangzhou, Zhejiang, China.
Hongsheng LiuDepartment of Pathology, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis from breast cancer (BC) to renal cell carcinoma (RCC) is rare. We retrospectively analyzed the clinical data, i.e., medical history, imaging, and laboratory examinations, as well as pathological features of a 62-year-old female with invasive ductal carcinoma of the breast metastasizing to clear cell renal cell carcinoma (CCRCC). A comprehensive literature review was also conducted. Her right breast mass was pathologically diagnosed as invasive ductal carcinoma eight months ago. A large mass in the left kidney was incidentally discovered during a computed tomography (CT) scan, which was consistent with RCC. She underwent neoadjuvant chemotherapy, radical mastectomy, and endocrine therapy, as well as laparoscopic left nephrectomy four months postoperatively. Her pathological examination revealed two heterogeneous tumor components in the kidney: typical CCRCC [CD10+, Vimentin+, carbonic anhydrase IX (CAIX)+, paired box gene 8 (PAX-8)+, 3% Ki-67 proliferation index) as well as multifocal metastatic invasive ductal carcinoma of the breast (estrogen receptor (ER) 50%+++, GATA binding protein 3 (GATA3) +, Human epidermal growth factor receptor-2 (HER-2) 1+, and 20% Ki-67 proliferation index). These findings met the diagnostic criteria for TTM. She also continued BC endocrine therapy postoperatively. However, no recurrence or metastasis was observed during the 11 follow-up months.

Indexed as

breast cancerclear cell renal cell carcinomaimmunohistochemistrymetastasispathological diagnosistumor-to-tumor

Identifiers

PMID41476587
PMCPMC12747989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.